Clinical trial NCT00983944 (phase 2, status: withdrawn)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: epoch regimen, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate
SMILES: CCO, ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Reason stopped: 
    inadequate accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary mediastinal (thymic) large B-cell lymphoma as defined
             by WHO classification of lymphoid neoplasms

               -  Diagnosis must be based on an adequate tissue sample, such as an excisional
                  biopsy or core-needle biopsy

          -  A paraffin-embedded block of well-fixed lymphoma tissue must be available

          -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1
             dimension as ≥ 10 mm

          -  No active or untreated CNS lymphoma

               -  A lumbar puncture is not required in the absence of neurologic symptoms

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  ANC ≥ 1,000/mm^3 (unless related to disease)

          -  Platelet count ≥ 100,000/mm^3 (unless related to disease)

          -  Total bilirubin ≤ 2.0 times upper limit of normal (ULN)

          -  AST and/or ALT ≤ 2.5 times ULN

          -  Creatinine ≤ 2.0 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Ejection fraction ≥ 45% by MUGA or echocardiogram

          -  Patients with HIV infection are eligible, provided the following criteria are met:

               -  No evidence of co-infection with hepatitis B or C

               -  CD4 cell count ≥ 400/mm^3

               -  No evidence of resistant strains of HIV

               -  HIV viral load ≤ 10,000 copies HIV RNA/mL (if not on anti-HIV therapy)

               -  HIV viral load ≤ 50 copies HIV RNA/mL (if on anti-HIV therapy)

               -  No history of AIDS-defining conditions

          -  No concurrent uncontrolled illness including, but not limited to, the following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements

          -  No active secondary malignancy except nonmelanomatous skin cancer

        PRIOR CONCURRENT THERAPY:

          -  No prior cytotoxic chemotherapy or rituximab

               -  Prior limited course of glucocorticoids allowed

          -  No other concurrent investigational or commercial anticancer therapies